Novo Nordisk (NOVOB DC) presents four new analyses on oral semaglutide including demonstrated reduction in cardiovascular risk factor; analyses to be presented at ObesityWeek 2025 (November 4-7, 2025)
05 Nov 2025 - 13:16- - Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts